Taiwan iPSC and stem cells companies and pipeline landscape (November 2026) | Drugnews
At least 6 Taiwanese biotech companies are active in iPSC and stem cells, with 7 assets in development or on the market. The most advanced is UnicoCell (6794)’s ELIXCYTE-CKD (Phase 2/3 IND application submitted to TFDA; Severe chronic kidney disease). Data as of 2026-11-01; updated as new information becomes available.
Taiwan pipelines
7 / 7
| UnicoCell (6794) | 6794 | ELIXCYTE-CKD | Not disclosed | Phase 2/3 IND application submitted to TFDA | Severe chronic kidney disease | Not disclosed | 2026-02-06 | 2026-02-06 2026-09-30 |
| UnicoCell (6794) | 6794 | ELIXCYTE-OA (allogeneic adipose-derived mesenchymal stem cells) | ELIXCYTE-OA (allogeneic adipose-derived mesenchymal stem cells) | Phase III; last patient enrolled | Knee osteoarthritis | Not disclosed | 2026-10-01 | 2026-07-06 2026-10-01 |
| BIONET (1784) | 1784 | BU-01 | Not disclosed | Phase 2 | Acute respiratory distress syndrome | Not disclosed | 2025-12-19 | 2025-12-19 |
| Meribank (4724) | 4724 | UMC119-06-05 | Not disclosed | Phase 1/2; active, not recruiting | Frailty in older adults | Not disclosed | 2024-07-08 | 2024-07-08 2024-07-15 |
| Ever Supreme (6712) | 6712 | UMSC01 | Allogeneic umbilical cord mesenchymal stem cells | Phase 1 / Phase 2; active not recruiting | COVID-19 Infection | Not disclosed | 2025-08-07 | 2025-08-07 2026-09-23 2026-09-23 2026-09-23 2026-09-23 2026-09-23 2025-08-07 2026-09-23 |
| BIONET TX (7808) | 7808 | BU01 (umbilical cord mesenchymal stem cells) | BU01 (umbilical cord mesenchymal stem cells) | Phase II | Pulmonary fibrosis | Not disclosed | 2026-09-20 | 2026-09-20 |
| Hexun (6986) | 6986 | HeXell-2020 (mesenchymal stem cells) | HeXell-2020 (mesenchymal stem cells) | Phase I/IIa; recruiting | Stable coronary artery disease | Not disclosed | 2026-09-25 | 2026-09-25 2026-09-29 |
No matches. Clear the search to show all rows.
Recent events
- 未公開 Source
- Published source records ELIXCYTE-OA (allogeneic adipose-derived mesenchymal stem cells): Phase III; last patient enrolled. Source
- Trial registry update records HeXell-2020 (mesenchymal stem cells): Phase I/IIa; recruiting. Source
- Published source records BU01 (umbilical cord mesenchymal stem cells): Phase II. Source
- Published source records ELIXCYTE-CKD: Phase 2/3 IND application submitted to TFDA. Source
- Published source records BU-01: Phase 2. Source
Related Drugnews analysis
FAQ
Which Taiwanese companies are developing iPSC and stem cells?
Currently, 6 companies are included: UnicoCell (6794), BIONET (1784), Meribank (4724), Ever Supreme (6712), BIONET TX (7808), Hexun (6986). Their drugs, stages and indications are in the pipeline table above.
Which Taiwan-listed stocks are linked to iPSC and stem cells?
Taiwan-listed companies directly involved in iPSC and stem cells R&D, manufacturing or licensing include: UnicoCell (6794), BIONET (1784), Meribank (4724), Ever Supreme (6712), BIONET TX (7808), Hexun (6986). Compiled from public information; this is not investment advice.
Which Taiwanese iPSC and stem cells program is most advanced?
UnicoCell (6794)’s ELIXCYTE-CKD is at Phase 2/3 IND application submitted to TFDA (Severe chronic kidney disease).
What is the latest important development in Taiwan’s iPSC and stem cells sector?
The latest record is 2026-10-01: Meribank (4724) 公告本公司開發之異體臍帶間質幹細胞治療慢性阻塞性 肺病製劑產品麥力優取得衛福部核發外銷專用藥品許可證。.
SourceHow often is this data updated?
Data as of 2026-11-01; updated when companies announce new developments or clinical progress. Every entry includes its original source and date.